Carl Zeiss Vision has launched the revolutionary NEW MyoVision Lens, the world’s first single vision spectacle lens clinically demonstrated to delay myopia progression by an average of 30 per cent when compared to traditional spectacle lenses.
The most widely used method for correcting myopia is traditional spectacle lenses. Traditional minus lenses correct for a child’s vision by placing the image on the retina, allowing the child to see clearly. However they will not delay the progression of a child’s myopia.
Contact lenses are used by some 10 per cent to 15 per cent of the population who need vision correction, mostly in the age group of 15 to 40 year olds. There are steps you can take to minimise myopia and its development.
MyoVision is a patented lens design with the revolutionary ‘Peripheral Vision Management Technology’. It has been clinically proven in wearer trials co-ordinated by Vision CRC Australia and conducted by Sun Yat-sen University, China. The delay of myopia progression if sustained over a number of years means that a child, who would normally have a prescription of -6.00D by the time he or she reached the age of 18, would now only have a prescription of -4.00D.
Carl Zeiss Vision collaborated with Professor Brien Holden and the team at Vision CRC in the development and research of the MyoVision lens.